Takeda stock rises 5.4% as launch strategy gains momentum

Takeda reported first-half FY2026 results on October 29, highlighting new product launches, pipeline progress and a higher full-year outlook. The release from Takeda adds fresh information to the company's launch-focused growth story.

Growth Still Depends On Execution

Revenue for the six months ended September 30 increased 8.4 percent at actual exchange rates but declined 1.0 percent at constant exchange rates. Core operating profit rose 11.2 percent at actual exchange rates and 0.7 percent at constant exchange rates, while reported operating profit benefited from the end of VYVANSE intangible-asset amortization and lower impairment charges.

Takeda said ORZEYFUL was approved in the United States, Japan and China for narcolepsy type 1, with launches already completed in Japan and China. MIMRYLO launched in the United States in August for erythrocytosis in polycythemia vera. Zasocitinib has received FDA Priority Review, while the European Medicines Agency is reviewing the application.

Higher Forecast, Currency Tailwind

Takeda raised its FY2026 revenue forecast to JPY 4.7 trillion from JPY 4.64 trillion and lifted its core operating profit forecast to JPY 1.19 trillion from JPY 1.16 trillion. The company said the upgrade mainly reflects a foreign-exchange benefit, while constant-exchange-rate guidance still points to a low-single-digit revenue decline.

Takeda stock traded at 19.50 euros on Lang & Schwarz at 15:29 CET on Thursday, November 5, 2026. That is 5.41 percent above the 18.50-euro Lang & Schwarz quote cited in the previous report on October 27. The comparison reflects the fresh euro quote against the earlier report, not a Xetra daily close.

Investors can follow the real-time quote of Takeda stock as launch execution, regulatory decisions and currency movements shape the outlook.

The S&P 500 provides the relevant broader market backdrop for Takeda's NYSE-listed American depositary shares.

Takeda will host its Capital Markets Day in Tokyo on December 11, when management is expected to present more detail on its longer-term growth strategy. More news and analyses on Takeda stock will track those developments.